



Optibrium Adopts Cheminformatics Toolkits From OpenEye Scientific

High performance libraries provide strong foundation for new developments to StarDrop drug discovery software

CAMBRIDGE, UK and SANTA FE, NEW MEXICO, USA: 12 April, 2020 – Optibrium™ and OpenEye Scientific (OpenEye), leading providers of software and services for drug discovery, today announced that StarDrop™, Optibrium's software for small molecule design, optimisation and data analysis, is now powered by OpenEye Scientific's cheminformatics toolkits. These industry-leading cheminformatics libraries offer a robust and performance-orientated foundation that ensures StarDrop will further advance its position as a leading computational software suite and meet the demands posed by future drug discovery projects.

Optibrium's lead product, StarDrop, is a comprehensive suite of integrated software deployed by many of the world's leading pharmaceutical and biotech companies to support their drug discovery programs. StarDrop's seamless integration of the industry-leading libraries and toolkits developed by OpenEye Scientific, including OEChem, OEDepict and OMEGA, enables accelerated development of Optibrium's *in silico* drug discovery technologies and artificial intelligence services.

OpenEye Scientific is an industry leader in the field of cheminformatics software for drug discovery, providing high-performance and robust libraries with a developer-friendly Application Programming Interface, supporting the development of highly customisable software solutions and workflows. The company directly supports pharmaceutical and biotechnology companies as well as making its cheminformatics platform available to software companies, such as Optibrium, enabling high-performance cheminformatics software solutions.

Dr. Anthony Nicholls, OpenEye Scientific's CEO commented: *"It's always exciting when we get the opportunity to empower great people with the same foundational software platform that has allowed us to grow and develop for the last twenty years. Optibrium has always had a fantastic product in StarDrop, and it's an honour to be a part of what they offer to the pharmaceutical industry."*

Dr Matthew Segall, Optibrium's CEO, said: *"We continue to invest in cutting-edge research to deliver high-quality science and new functionality that is accessible within StarDrop's intuitive user interface, to the benefit of our global user base. We highly value this collaboration with OpenEye Scientific, a company that shares our commitment to creating best-in-class technologies designed for reliability and performance."*

The companies continue to work closely together to leverage future opportunities to advance their respective platforms.

For further information on StarDrop, please visit www.optibrium.com/stardrop/, contact info@optibrium.com or call +44 1223 815900.

For more information on OpenEye's OEChem, OEDepict and OMEGA, go to: www.eyesopen.com/oechem-tk, contact sales@eyesopen.com or call +1-505-473-7385

ENDS

Notes to Editors:



Matt Segall, CEO, Optibrium

For high resolution images please email sarah.jeffery@zymecommunications.com



Anthony Nicholls, CEO and Founder, OpenEye Scientific

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com
To view our privacy policy, [please click here](#)

Media contact

Grace Holland
Zyme Communications
E-mail: grace.holland@zymecommunications.com
Phone: +44 (0)7530 386228

Optibrium

John Norman
Head of Marketing
E-mail: john@optibrium.com
Phone: +44 (0)1223 815903

OpenEye Scientific

Jeffrey Grandy
Chief Commercial Officer
E-mail: jeff@eyesopen.com
Phone: +1- 415-863-3032

About Optibrium Ltd

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium's lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company's new Augmented Chemistry™ products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement researchers experience and skills.

Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

For further information visit www.optibrium.com or join in discussions on improving the productivity of drug discovery at www.optibrium.com/community.

About OpenEye Scientific

OpenEye has built a reputation as a scientific leader in the field of molecular design based on two decades of delivering useful applications, programming toolkits, Software as a Service (SaaS) and discovery services. Its scientific approach has focused on the power of molecular 3D structure to inform and guide, in particular via the concept of shape similarity. OpenEye has changed the industry perception of what is possible with the speed, robustness and scalability of its tools and has recently built these into a cloud-native discovery platform, Orion. Combining unlimited computation and storage with powerful tools for data sharing, visualization and analysis in an open development platform, Orion offers unprecedented capabilities for drug discovery and optimization. OpenEye Scientific is a privately held company headquartered in Santa Fe, New Mexico, with offices in Boston, Massachusetts, Cologne, Germany, Strasbourg, France and Tokyo, Japan. Visit www.eyesopen.com for full details.